Skip to main content

Table 1 Demographic information of study participants for high-throughput antibody microarray screening

From: Protein profiling in systemic sclerosis patients with different pulmonary complications using proteomic antibody microarray

Group

No

Age (year)

Gender

Course (year)

Subtype

Modified Rodnan Skin Score

Right heart catheter

Echocardiography

ILD in HRCT

mPAP (mmHg)

PCWP (mmHg)

TRV (m/s)

SSc-PAH

1

56

Female

1.38

dcSSc

15

65

8

4.7

No

2

53

Male

3.78

lcSSc

4

59

11

4.7

No

3

50

Female

17.36

lcSSc

2

59

15

4.1

No

4

43

Female

7.07

lcSSc

2

66

10

5.0

No

5

34

Female

1.00

lcSSc

4

43

10

-

No

SSc-ILD

6

39

Male

12.70

dcSSc

17

-

-

2.2

Yes

7

36

Female

4.40

lcSSc

2

-

-

2.3

Yes

8

22

Female

4.69

lcSSc

9

-

-

2.3

Yes

9

55

Female

20.10

lcSSc

7

-

-

2.5

Yes

10

58

Female

12.80

lcSSc

7

-

-

2.8

Yes

SSc-nonPAH-nonILD

11

34

Female

0.86

dcSSc

15

-

-

2.3

No

12

35

Female

2.66

lcSSc

2

-

-

2.5

No

13

47

Male

1.45

dcSSc

17

-

-

2.8

No

14

41

Female

13.38

lcSSc

8

-

-

2.2

No

15

52

Female

10.12

lcSSc

5

-

-

2.5

No

HC

16

41

Male

-

-

-

-

-

-

-

17

26

Female

-

-

-

-

-

-

-

18

53

Female

-

-

-

-

-

-

-

19

43

Female

-

-

-

-

-

-

-

20

52

Female

-

-

-

-

-

-

-

  1. PAH Pulmonary arterial hypertension, ILD Interstitial lung disease, HC healthy control, dcSSc diffuse cutaneous systemic sclerosis, lcSSc limited cutaneous systemic sclerosis, mPAP mean pulmonary arterial pressure, PCWP pulmonary capillary wedge pressure, TRV tricuspid regurgitation velocity, HRCT high resolution computed tomography
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us